GlassScriptPhysician profile
Vikas K Patel
NPI 1194165738
$3,018.29
in general payments reported to CMS, 2019-2025
17 companies · $340 in 2025
The $340 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.79 · 2021: $393 · 2022: $547 · 2023: $550 · 2024: $1,105 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,994.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,129.89 | 2019-2025 | |
| Abbvie INC. | $824.36 | 2021-2025 | |
| Genzyme Corporation | $318.71 | 2021-2025 | |
| Janssen Biotech, INC. | $150.15 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.47 | 2024 | Spevigo |
| Ucb, INC. | $80.12 | 2023-2024 | Bimzelx |
| Dermavant Sciences, INC. | $75.20 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $63.27 | 2024-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $51.11 | 2021-2024 | Dupixent |
| Smith+Nephew, INC. | $34.45 | 2019 | |
| Amgen INC. | $33.39 | 2023 | Otezla |
| Lilly USA, LLC | $32.62 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $29.84 | 2023 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $27.80 | 2025 | Sotyktu |
| Botanix Sb INC | $23.99 | 2025 | Sofdra |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $13.34 | 2021 | |
| Organon LLC | $5.58 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.